These Ago2-mediated molecular events may solve the paradox of protein biosynthesis in the obese liver, demonstrate a new mechanism in the regulation of basal metabolic activity, and provide a novel therapeutic target for metabolic diseases. The gene discussed is AGO2; the disease is metabolic disease.